Denali Therapeutics (DNLI)
(Real Time Quote from BATS)
$25.77 USD
+1.00 (4.04%)
Updated Aug 26, 2024 01:12 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Cash flow Statements
Fiscal Year End for Denali Therapeutics Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -145.22 | -325.99 | -290.58 | 71.14 | -197.61 |
Depreciation/Amortization & Depletion | -27.23 | 8.75 | 17.34 | 8.59 | 2.97 |
Net Change from Assets/Liabilities | -289.93 | -24.03 | -20.41 | 288.40 | 4.18 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 104.39 | 96.56 | 82.26 | 48.03 | 38.89 |
Net Cash From Operating Activities | -357.99 | -244.72 | -211.39 | 416.15 | -151.58 |
Property & Equipment | -12.94 | -17.83 | -8.50 | -3.10 | -17.92 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 262.25 | -123.55 | -13.13 | -620.11 | 165.63 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 249.31 | -141.39 | -21.63 | -623.21 | 147.71 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 17.82 | 14.46 | 19.35 | 440.80 | 6.19 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 296.22 | 0.00 | 193.95 | 0.00 |
Net Cash from Financing Activities | 17.82 | 310.67 | 19.35 | 634.75 | 6.19 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -90.86 | -75.43 | -213.67 | 427.70 | 2.33 |
Cash at Beginning of Period | 219.54 | 294.98 | 508.64 | 80.95 | 78.62 |
Cash at End of Period | 128.68 | 219.54 | 294.98 | 508.64 | 80.95 |
Diluted Net EPS | -1.06 | -2.60 | -2.39 | 0.63 | -2.07 |
Fiscal Year End for Denali Therapeutics Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -200.83 | -101.80 | -145.22 | -25.75 | 73.60 |
Depreciation/Amortization & Depletion | -16.47 | -8.35 | -27.23 | -17.16 | -7.05 |
Net Change from Assets/Liabilities | -23.97 | -15.81 | -289.93 | -295.78 | -291.37 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 36.43 | 12.35 | 104.39 | 79.35 | 52.85 |
Net Cash From Operating Activities | -204.84 | -113.62 | -357.99 | -259.33 | -171.97 |
Property & Equipment | -6.94 | -2.15 | -12.94 | -10.70 | -8.64 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -347.68 | -451.04 | 262.25 | 186.97 | 83.99 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -354.62 | -453.19 | 249.31 | 176.26 | 75.35 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 507.03 | 500.28 | 17.82 | 13.12 | 10.62 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 507.03 | 500.28 | 17.82 | 13.12 | 10.62 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -52.43 | -66.53 | -90.86 | -69.96 | -86.00 |
Cash at Beginning of Period | 128.68 | 128.68 | 219.54 | 219.54 | 219.54 |
Cash at End of Period | 76.25 | 62.15 | 128.68 | 149.59 | 133.55 |
Diluted Net EPS | -0.59 | -0.68 | -0.84 | -0.72 | 1.30 |